New STXS management is experienced and has major skin in the game, with insiders owning 67% of the outstanding shares.
STXS is finally unburdened by debt and has enough cash to reach consistent profitability.
STXS has a large installed base of machines in hospitals worldwide that is generating about $7 million per quarter in recurring revenue at an 80% margin.
STXS is a no-brainer bolt-on acquisition for many robotic surgery companies,with its superior and patented robotic technology, and a high-margin razor/razor-blade business.
A Highly Undervalued Company In A Hot Market For Acquisitions Creates A Rare Opportunity
Stereotaxis (STXS) has developed an innovative magnetic robotic surgery system for repairing heart arrhythmias and other heart conditions. Extensive